Esoblend-D Capsule SR is a combination pharmaceutical formulation containing Domperidone 30 mg and Esomeprazole 40 mg, designed for the management of gastrointestinal disorders involving acid reflux and delayed gastric emptying. Domperidone, a peripheral dopamine D2 receptor antagonist, facilitates gastric motility and accelerates gastric emptying, thereby reducing symptoms such as nausea, vomiting, and bloating. Esomeprazole, a proton pump inhibitor (PPI), suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, effectively reducing gastric acidity and promoting mucosal healing. The sustained-release (SR) formulation ensures prolonged therapeutic plasma concentrations, enhancing efficacy and patient compliance through once-daily dosing. Esoblend-D Capsule SR is indicated for the treatment of gastroesophageal reflux disease (GERD), erosive esophagitis, and other acid-related disorders, particularly in patients exhibiting delayed gastric emptying or associated dyspeptic symptoms. It should be administered under medical supervision, with caution advised in patients with underlying cardiac conditions or those taking medications that may interact with domperidone or esomeprazole. Common adverse effects may include headache, dry mouth, or gastrointestinal disturbances. This combination offers a synergistic approach by addressing both acid suppression and motility enhancement, improving overall symptom control and quality of life in affected patients.